Publications

Show Filters

Searches all publications.

Search Term

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24

Articles

254624 items
12:00 AM, May 09, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

PilaSite data

INSV (Alameda, Calif.) presented initial Phase III results showing that over three months, average intraocular pressure dropped by 20 percent (5.5 mm Hg) in both the 100 patients who received the PilaSite eye drops twice...
12:00 AM, May 09, 1994  |  BioCentury | Strategy

MPRO Sacrifices Disputed Product

MPRO sacrifices disputed product MicroProbe Corp. withdrew its Affirm VP line of DNA probe-based products from the market to avoid the costs of litigating a patent dispute with Gen-Probe Inc., but said it believes it...
12:00 AM, May 09, 1994  |  BioCentury | Politics, Policy & Law

White House signals it won't fight; How VCs adjust to threat of price controls

White House signals it won't fight WASHINGTON - A delegation of California biotechnology and health care executives received assurances last week from Ira Magaziner, President Clinton's top advisor on health care reform, that the administration...
12:00 AM, May 09, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

BotB data

ATHN (South San Francisco) announced findings of three open-label Phase I trials in 32 patients, who received a total of 72 injections of the toxin, ranging from 100 to 2400 units. Doses greater than 900...
12:00 AM, May 09, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

AnervaX vaccine: Began Phase I dose escalation trial

Anergen Inc. (ANRG), Redwood City, Calif.   Product: AnervaX vaccine, a synthetic peptide that elicits an antibody response against molecules of the major histocompatibility complex (MHC) that present self-antigens to T-cells   Indication: Rheumatoid arthritis   Status: Began...
12:00 AM, May 09, 1994  |  BC Week In Review | Company News  |  Other News

Hybridon news

Hybridon signed a 10-year lease for a 36,000 square foot production facility in Milford, Mass., to produce antisense oligonucleotide compounds for clinical trials. The Worcester, Mass., compeny plans to spend $4-5 million to retrofit the...
12:00 AM, May 09, 1994  |  BioCentury | Product Development

What Alpha-Beta learned in trial

Angry investors hammered Alpha-Beta Technology Inc. stock amid concerns over the company's timeline for entering Phase III studies of Betafectin and following an unfriendly reception to the presentation of its second Phase I/II study at...
12:00 AM, May 09, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

CT-1501R data

The Seattle company presented animal data on three different indications for lisofylline (CT-1501R), an inhibitor of the Bursten pathway, an intracellular, second messenger pathway that is activated in response to cell damaging stimuli. CT-1501R prevented...
12:00 AM, May 09, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

Interleukin-6 mutein: Filed IND

ImClone Systems Inc. (IMCL), New York, N.Y.   Product: Interleukin-6 mutein (IL-6m), a variant of the natural cytokine that regulates marrow production of platelets   Indication: Thrombocytopenia associated with chemotherapy   Status: Filed IND in U.S.; the...
12:00 AM, May 09, 1994  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

BioChem Pharma Inc. (BCHXF) Edmund Debler of Mehta and Isaly repeated a "buy", saying BCHXF's purchase of Serono Diagnostics will augment an existing profitable business, with potential major cost savings from the combined operations. The...

Pages